Time scale and adjusted survival curves for marginal structural Cox models

American Journal of Epidemiology

Volumn 171, Issue 6, 2010, Pages 691-700

  Westreich, Daniel ^a   Cole, Stephen R ^a   Tien, Phyllis C ^b,c   Chmiel, Joan S ^d   Kingsley, Lawrence ^e   Funk, Michele Jonsson ^a   Anastos, Kathryn ^f   Jacobson, Lisa P ^g  

^a IL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy, highly active; Bias (epidemiology); Causal inference; Confounding factors (epidemiology); Proportional hazards model; Survival curve; Survival time

Indexed keywords

ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; EPIDEMIOLOGY; HAZARD ASSESSMENT; MEDICAL GEOGRAPHY; PUBLIC HEALTH; SURVIVAL; TIMESCALE;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MARGINAL STRUCTURAL COX MODEL; MORTALITY; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77949401712     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp418     Document Type: Article

References (40)

1. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer; 2003.
2. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145(1):72-80.
3. Lamarca R, Alonso J, Gómez G, et al. Left-truncated data with age as time scale: an alternative for survival analysis in the elderly population. J Gerontol A Biol Sci Med Sci. 1998;53(5): M337-M343.
4. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9): 915-920.
5. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560.
6. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B). 1972;34(2):187-220.
7. Barrón Y, Cole SR, Greenblatt RM, et al. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS. 2004;18(11):1579-1584.
8. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173-1177.
9. Cole SR, Hernán MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158(7):687-694.
10. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol. 2002;155(11):1045-1053.
11. Fox MP, Brooks DR, Kuhn L, et al. Role of breastfeeding cessation in mediating the relationship between maternal HIV disease stage and increased child mortality among HIV-exposed uninfected children. Int J Epidemiol. 2009;38(2): 569-576.
12. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5): 561-570.
13. Hernán MA, Brumback BA, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001;96(454):440-448.
14. López-Gatell H, Cole SR, Hessol NA, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol. 2007;165(10):1134-1142.
15. López-Gatell H, Cole SR, Margolick JB, et al. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. AIDS. 2008;22(14):1869-1873.
16. Sterne JA, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483): 378-384.
17. Wiesbauer F, Heinze G, Mitterbauer C, et al. Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol. 2008;19(11):2211-2218.
18. Gail MH, Graubard B, Williamson DF, et al. Comments on 'Choice of time scale and its effect on significance of predictors in longitudinal studies' by Michael J. Pencina, Martin G. Larson, and Ralph B. D'Agostino, Statistics in Medicine 2007;26:1343-1359. Stat Med. 2009;28(8):1315-1317.
19. Pencina MJ, Larson MG, D'Agostino RB. Choice of time scale and its effect on significance of predictors in longitudinal studies. Stat Med. 2007;26(6):1343-1359.
20. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45-49.
21. Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24(20):3089-3110.
22. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987; 126(2):310-318.
23. Barkan SE, Melnick SL, Preston-Martin S, et al. TheWomen's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9(2):117-125.
24. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
25. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: AIDSinfo (formerly HIV/AIDS Treatment Information Service), National Institutes of Health, 2000. (http://www.aidsinfo.nih.gov).
26. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption? Epidemiology. 2009; 20(1):3-5.
27. Hernán MA, Taubman SL. Does obesity shorten life? The importance of well-defined interventions to answer causal questions. Int J Obes (Lond). 2008;32(suppl 3):S8-S14.
28. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008; 168(6):656-664.
29. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006; 60(7):578-586.
30. D'Agostino RB, Lee ML, Belanger AJ, et al. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med. 1990;9(12): 1501-1515.
31. Abbott RD. Logistic regression in survival analysis. Am J Epidemiol. 1985;121(3):465-471.
32. Allison PD. Discrete-time methods for the analysis of event histories. In: Sociological Methodology Vol. 13. Hoboken, NJ: John Wiley & Sons; 1982. 61-98.
33. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11): 725-733.
34. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280(17):1497-1503.
35. Greenland S. Absence of confounding does not correspond to collapsibility of the rate ratio or rate difference. Epidemiology. 1996;7(5):498-501.
36. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-625.
37. Cain LE, Cole SR, Chmiel JS, et al. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. Am J Epidemiol. 2006; 163(4):310-315.
38. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-779.
39. Cole SR, Hernán MA, Anastos K, et al. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol. 2007;166(2):219-227.
40. Cole SR, Hernán MA, Margolick JB, et al. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol. 2005; 162(5):471-478.